Mechanism of Action
RXFP2 Receptor Signaling
INSL3 binds RXFP2 with high affinity and activates adenylyl cyclase via Gs proteins, elevating cAMP. In gubernacular cells during fetal development, this drives tissue remodeling and testicular descent. In adult bone, RXFP2 signaling stimulates osteoblast differentiation and bone formation. In the testis, INSL3 modulates germ cell development and testicular blood flow via RXFP2 on peritubular myoid cells.
Fetal Development Role
INSL3 knockout mice exhibit bilateral cryptorchidism (retained testes) due to failed gubernacular development, establishing INSL3 as the critical signal for the first transabdominal phase of testicular descent. Human RXFP2 mutations cause cryptorchidism in boys. This developmental function is distinct from the adult endocrine roles.
Research Summary
Male Reproductive Health Biomarker
Clinical EvidenceAdult serum INSL3 levels are a direct quantitative marker of functional Leydig cell mass, more sensitive than testosterone for detecting Leydig cell dysfunction. Low INSL3 with normal testosterone indicates Leydig cell reserve depletion. It is reduced in varicocele, aging, chemotherapy-exposed men, and Klinefelter syndrome. INSL3 measurement is gaining clinical utility for male reproductive assessment.
Bone Metabolism
PreclinicalINSL3 via RXFP2 promotes osteoblast activity and bone formation in vitro and in vivo. INSL3 knockout mice show reduced bone mass. In human osteoporosis cohorts, low serum INSL3 associates with reduced bone mineral density in men, suggesting INSL3 may contribute to the androgen-independent bone protective effects of the male gonadal axis.
Calculate your Insulin-Like Peptide 3 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Leydig cell function assessment | N/A | Morning serum draw | Blood draw (ELISA) |
| Bone formation (rodent) | 1-10 ug/kg SC | Daily x 28 days | Subcutaneous |
| Cryptorchidism rescue (neonatal rodent) | Continuous SC infusion | Postnatal days 1-7 | Subcutaneous |
Human therapeutic use is speculative. INSL3 is primarily a research and biomarker tool. No clinical trials for exogenous INSL3 administration in humans.
Interactions
Safety Profile
No human administration safety data for exogenous INSL3. As an endogenous peptide with constitutive Leydig cell production, physiological INSL3 appears well tolerated. Theoretical concerns for supraphysiological dosing include RXFP2 desensitization and effects on osteoblast/gonadal axis. No commercial therapeutic INSL3 product exists.
References
- [1]Ivell R, Anand-Ivell R. Biological role and clinical significance of insulin-like peptide 3. Curr Opin Endocrinol Diabetes Obes. 2009;16(3):210-214.
- [2]Nef S, Parada LF. Cryptorchidism in mice mutant for Insl3. Nat Genet. 1999;22(3):295-299.
- [3]Bay K, et al. Insulin-like factor 3 levels in cord blood and serum from children: effects of age, gestational age, and weight. J Clin Endocrinol Metab. 2007;92(12):4636-4641.